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with penumococci, several boundaries and weaknesses in modeling occur: only steady 
state analysis possible; no dynamic implementation of herd immunity and replacement 
effects; and no inﬂuence of changing demographic structure over time Therefore a 
comparable ODE system was implemented and extended by population dynamics and 
splitting the pneumococcal serotypes in groups depending on their behavior depending 
on immunization. RESULTS: For standard immunization program implementation as 
advocated by EPAR/EMEA it was possible to reproduce the behaviour of the Markov-
ian-Model with the ODE approach resulting in equivalent outcomes for validation.
Using ODE approach extensions the inﬂuence of population dynamic effects with and 
without immunization is compared in detail. Using the mathematical theory for ODEs 
stability and uniqueness of the implemented approach was shown. CONCLUSIONS: 
The Markovian model can accurately describe the infection with pneumococcal bac-
teria if proper data exists and if there is no need to use dynamic effects or feedback-
loops. The ODE model offers possibilities to implement additional dynamic methods, 
which is essential to gather the real world dynamics.
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OBJECTIVES: The aim of this project is to generate an assessment for the new pneu-             
mococcal non-typeable Haemophilus inﬂuenzae protein-D conjugate vaccine (PHiD-
CV) in Italy. Currently, pneumococcal vaccination is not recommended nationally,          
but many regions adopted 7-valent pneumococcal (PCV-7) vaccination.    METHODS: 
The project was performed using the Health Technology Assessment (HTA) methodol-
ogy with a large input of multidisciplinary panel of experts with different backgrounds 
such as clinicians, epidemiologists and health economists. RESULTS: Literature and  
national database review revealed at least 300 pneumococcal meningitis and 4.000 
pneumococcal bacteremia cases per year in Italy. The additional pneumococcal sero-
types (ST) included in PHiD-CV (ST1, 5 and 7F) account for at least 10% of all 
Invasive Pneumococcal Disease (IPD) cases. The amount of pneumococcal and NTHi 
pneumonia cases was estimated at around 70.000 cases per year. More than one 
million infant episodes of otitis media (OM) are reported annually. Around 50% of 
these cases are caused by two bacteria, Streptococcus pneumonia and NTHi. The total 
annual direct medical cost related to pneumococcal and NTHi disease could exceed 
110 million Euros in Italy. Modelling the impact of PHiD-CV vaccine with a cohort 
model populated with Italian data shows a huge health gain in IPD, pneumonia and 
OM. The new vaccine demonstrates superior clinical results and important cost-offsets 
compared with no vaccination. It dominates as well the current vaccination option of 
PCV-7, leading to signiﬁcant cost savings. CONCLUSIONS: Pneumococcal vaccina-
tion emerges as an important public health improvement in Italy; at the same price, 
PHiD-CV appears the preferable choice for routine child immunization programs.
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OBJECTIVES: Gout patients in the Department of Veterans Affairs (VA) are often 
difﬁcult to manage (DTM) with multiple co-morbidities (diabetes, hypertension, renal 
disease) that are associated with cardiovascular thrombotic events (CVTE) and other 
cardiac events (OCE). Our objectives were to describe rates of CVTE and OCE among 
patients with gout and to determine if increased CVTE or OCE occurred in patients 
with DTM gout. METHODS: We used VA national databases to select all patients 
with gout diagnoses (ICD-9  274.xx) in an index year of 2004 with follow-up 
through 2006. We identiﬁed patients with ICD-9 codes for OCEs and CVTE diagno-
ses, based upon deﬁnitions from the Antiplatelet Trialists’ Collaboration. ICD-9 codes 
for gout nephropathy or tophi were used to identify DTM patients. We calculated 
odds ratios with 95% conﬁdence intervals (OR, CI) to compare risk of CVTE, OCE, 
and mortality among DTM versus other gout patients. RESULTS: Of 156,809 VA 
gout patients, 2534 (1.6%) had CVTE and 9759 (6.2%) had OCE in 2004. Rates 
were similar for 2005 and 2006: 1.6% and 1.3% for CVTE, 6.2% and 5.7% for 
OCE. DTM patients, deﬁned as having diagnostic codes of gout nephropathy (ICD-9 
of 274.1x, n  1667) and/or tophi (ICD-9 of 274.8x, n  1780), had similar rates of 
CVTE as other gout patients in 2004 (1.9% vs. 1.6%, OR  1.16, CI  0.90–1.50), 
but increased risk in 2005 (2.2% vs. 1.5%, OR  1.41, CI  1.13–1.77) and 2006 
(2.0% vs. 1.3%, OR  1.54, CI  1.23–1.93). OCEs were signiﬁcantly greater each 
year in DTM gout patients; 2004: 9.9% vs. 7.6%, OR  1.33, CI  1.19–1.50; 2005: 
11.1% vs. 7.4%, OR  1.57, CI  1.41–1.74; 2006: 11.3% vs. 6.8%, OR  1.75, CI 
 1.58–1.94. Mortality was signiﬁcantly greater in DTM gout patients; 2004: 3.3% 
vs. 4.0%, OR  1.21, CI  1.01–1.44; 2005: 3.3% vs. 4.8%, OR  1.49, CI  1.28–
1.73; 2006: 3.2% vs. 4.6%, OR  1.49, CI  1.27–1.73. CONCLUSIONS: Patients 
with DTM gout have greater risks for CVTEs, OCEs, and mortality.
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OBJECTIVES: Comparison of leﬂunomide, methotrexate and sulfasalazine safety 
based on data from WHO Programme for International Drug Monitoring. METHODS: 
The data from countries participating in the World Health Organization Programme 
for International Drug Monitoring are collected and maintained, on behalf of the 
WHO, by the Uppsala Monitoring Centre, in the Vigibase. An analysis of data on 
adverse events (AE) of leﬂunomide, methotrexate and sulfasalazine reported to Vigi-
base since 2000 up to 16th March 2009 (ref: ER18-2009), was performed. RESULTS: 
The total number of 16,311 individual case reports of leﬂunomide adverse events were 
registered in the Vigibase, compared to 32,945 and 5,011 for methotrexate and sul-
fasalazine, respectively. There were 108 death cases registered for leﬂunomide, 236 
for methotrexate and 18 for sulfasalazine. Most frequent system-organ classes reported 
were: gastro-intestinal system disorders (13.2%) and skin and appendages disorders 
(9,8%) for leﬂunomide, respiratory system disorders (11.6%) and general disorders 
(10.8%) for methotrexate and skin and appendages disorders (17.7%) and general 
disorders (14.6%) for sulfasalazine. Most frequent AE reports for leﬂunomide were: 
diarrhoea (588 cases versus 303 and 58 for methotrexate and sulfasalazine, respec-
tively), dyspnoea (310 vs. 563 vs. 53), hepatic function abnormal (304 vs. 262 vs. 78), 
nausea (272 vs. 401 vs. 90), rash (270 vs. 181 vs. 209), hypertension (265 vs. 138 vs. 
6) and anaemia (242 vs. 383 vs. 55). Congenital abnormalities were reported in 26 
leﬂunomide, 204 methotrexate and 15 sulfasalazine patients. CONCLUSIONS: WHO 
data indicates that leﬂunomide is at least as safe as methotrexate. All three disease 
modifying drugs have different spectrum of adverse events.
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OBJECTIVES: The primary objective was to estimate the proportion of patients suf-
fering from osteoporosis among postmenopausal women who could beneﬁt from 
therapeutic recommendations according to the French guidelines after performing a 
BMD diagnosis measurement. METHODS: Cross sectional observational study was 
performed of postmenopausal women, not treated for osteoporosis for at least one 
year and who could beneﬁt from therapeutic recommendations according to the 
French guidelines after performing a BMD. RESULTS: A total of 647 postmenopausal 
women were enrolled (646 analyzed) by 78 rheumatologists performing BMD mea-
surement between May 2007 and January 2008. The BMD measurement were pre-
scribed by rheumatologists (42.6%), GPs (34.1%), Ob/Gynecologist (18.1%) or other 
physicians (5.1%). The mean age was 66 o 9 years. According to the WHO deﬁnition, 
densitometry osteoporosis diagnosis was made in 57.6% patients (IC95% 53.7; 61.4), 
osteopenia diagnosis in 38.7% patients (IC95% 34.9; 42.6); and a normal BMD was 
established in 3.7% patients. A total of 39.7% of patients had at least a prevalent 
fracture and a treatment other than calcium and vitamin D supplementation was rec-
ommended in 93.0% cases of osteoporosis, in 44.8% in case of osteopenia and 8.3% 
in case of normal BMD. In a logistic regression model, the factors inﬂuencing thera-
peutic decision making in this population were the osteoporosis diagnosis versus 
osteopenia diagnosis OR  21.0 (IC95% 12.5; 35.3), past or current glucocorticoids 
use OR  2.7 (IC95% 1.3; 5.7). The fracture type was also important in decision making; 
existing vertebral fracture versus none OR  17.2 (IC95% 5.8; 51.4), existing non ver-
tebral fracture versus none OR  4.7 (IC95% 2.7; 8.4). CONCLUSIONS: In a real 
setting, osteoporosis was diagnosed in approximately 60% of the women who under-
went a BMD diagnosis and who complied with the French therapeutic guidelines. 
Therapeutic recommendations decision making was inﬂuenced mainly by BMD 
results, followed by prevalent fracture and fracture types and glucocorticoids use.
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OBJECTIVES: To evaluate the efﬁcacy and safety of the centrally acting analgesic, 
tapentadol ER, for the management of moderate to severe osteoarthritis knee pain; 
health status was evaluated using the EuroQol-5 Dimension (EQ-5D) questionnaire. 
